Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TRDA 
Entrada Therapeutics Inc (TRDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TRDA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.5
1 Year Target Price $18.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.73% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 235.07M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 4 | Beta -0.11 | 52 Weeks Range 4.93 - 21.79 | Updated Date 10/17/2025 |
52 Weeks Range 4.93 - 21.79 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -92.3% | Operating Margin (TTM) -2402.51% |
Management Effectiveness
Return on Assets (TTM) -11.66% | Return on Equity (TTM) -18.13% |
Valuation
Trailing PE - | Forward PE 3333.33 | Enterprise Value -74089493 | Price to Sales(TTM) 2.96 |
Enterprise Value -74089493 | Price to Sales(TTM) 2.96 | ||
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA 1.58 | Shares Outstanding 38037079 | Shares Floating 19080962 |
Shares Outstanding 38037079 | Shares Floating 19080962 | ||
Percent Insiders 12.3 | Percent Institutions 78.06 |
Upturn AI SWOT
Entrada Therapeutics Inc
Company Overview
History and Background
Entrada Therapeutics, Inc. is a biopharmaceutical company founded in 2016. It focuses on developing intracellular therapeutics to treat diseases with significant unmet medical needs. It has grown through its proprietary Endosomal Escape Vehicle (EEV) platform.
Core Business Areas
- Endosomal Escape Vehicle (EEV) Therapeutics: Developing a pipeline of oligonucleotide-based therapeutics that can effectively enter cells and address intracellular targets.
Leadership and Structure
The leadership team includes Dipal Doshi, President and CEO. The organizational structure reflects a typical biotech company with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- ENTR-601-44 (Duchenne Muscular Dystrophy - DMD): ENTR-601-44, is designed to selectively bind and restore dystrophin production in patients with DMD who are amenable to exon 44 skipping. Currently in clinical trials. Competitors include Sarepta Therapeutics and Solid Biosciences.
- ENTR-701 (Myotonic Dystrophy Type 1 - DM1): ENTR-701 is designed to reduce mutant DMPK mRNA in the nucleus. Competitors include Avidity Biosciences and Biogen.
Market Dynamics
Industry Overview
The industry involves developing oligonucleotide-based therapeutics targeting intracellular mechanisms, an area of active research and investment.
Positioning
Entrada Therapeutics is positioned as an innovative company leveraging its EEV platform to overcome the challenges of intracellular drug delivery. Its competitive advantage lies in its proprietary technology.
Total Addressable Market (TAM)
The TAM for diseases like DMD and DM1 is substantial. The specific figures vary by indication and market penetration, potentially reaching billions of dollars. Entrada aims to capture a significant portion of this TAM with effective therapies.
Upturn SWOT Analysis
Strengths
- Proprietary EEV platform
- Strong intellectual property portfolio
- Experienced leadership team
- Promising preclinical and clinical data
Weaknesses
- Reliance on a single technology platform
- Early-stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
Opportunities
- Expansion of the EEV platform to new targets and indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Increasing investment in oligonucleotide therapeutics
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles and delays
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- SRPT
- AVDL
- IONS
Competitive Landscape
Entrada's competitive advantage lies in its EEV platform, but it faces competition from established players with approved therapies and advanced clinical programs. Smaller Market Share as compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Entrada's growth has been primarily driven by the development and advancement of its EEV platform and pipeline programs.
Future Projections: Future growth is dependent on successful clinical trial results and regulatory approvals. Analyst projections vary but generally reflect optimism regarding the potential of the EEV platform.
Recent Initiatives: Recent initiatives include advancing ENTR-601-44 and ENTR-701 into clinical trials, expanding the pipeline to new indications, and forging strategic partnerships.
Summary
Entrada Therapeutics is a promising early-stage biotech company with a novel drug delivery platform. Its success hinges on the outcome of clinical trials, which represent a high-risk, high-reward scenario. The company needs to carefully manage its cash reserves and navigate the regulatory landscape. Positive clinical data could lead to significant value creation, while setbacks could negatively impact its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entrada Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | CEO & Director Mr. Dipal Doshi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.entradatx.com |
Full time employees 183 | Website https://www.entradatx.com | ||
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.